Current Report Filing (8-k)
14 April 2017 - 6:16AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 13, 2017 (April 10, 2017)
Neuralstem, Inc.
(Exact name of registrant as specified in Charter)
Delaware
|
|
001-33672
|
|
52-2007292
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
20271 Goldenrod Lane, 2
nd
Floor, Germantown, Maryland
20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On April 10, 2017, the compensation committee (“Committee”) of Neuralstem, Inc. (the “Company”)
recommended and the board of directors (“Board”) approved the reinstatement of non-employee Board compensation for
the period between July 1, 2016 and July 1, 2017. Upon reviewing the Company’s cash position, resulting primarily from its
receipt of a $20,000,000 strategic investment from Tianjin Pharmaceutical Group International Holdings Co., Ltd., the Board and
Committee determined that the previously deferred annual compensation of $100,000 per non-employee member of the Board would be
reinstated and paid, at the election of each director (i) in cash, (ii) in conditional stock option grants, subject to the applicable
NASDAQ rules or (iii) a combination thereof.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
|
April 13, 2017
|
Neuralstem, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Richard Daly
|
|
|
|
By: Richard Daly
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2024 to May 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Neuralstem Inc (NASDAQ): 0 recent articles
More Neuralstem, Inc. News Articles